Bio Monthly (April 2026): BioXP Upgrade, PeptAI Ignition Sale, How AI Is Rewriting DeSci
Highlights from April in the Biosphere 🌐PEPTAI Ignition Sale: The PeptAI Ignition Sale went live on Bio and is 12.9x oversubscribed as of this writing, with 610K+ USDC committed by 650+ participants. The sale closes Thursday, May 14 at 1pm UTC.BIO Staking: BIO staking is the gateway to Ignition Sales, giving stak...
PEPTAI Ignition Sale: The PeptAI Ignition Sale went live on Bio and is 12.9x oversubscribed as of this writing, with 610K+ USDC committed by 650+ participants. The sale closes Thursday, May 14 at 1pm UTC.
BIO Staking: BIO staking is the gateway to Ignition Sales, giving stakers automatic airdrops from new token launches and providing passive yield as the network expands. At TGE, 20% of the total supply is airdropped to veBIO holders pro-rata (Airdrop = Your veBIO × Airdrop Pool / Total veBIO), with no cap and no non-linear scaling. Staking before pledging also accrues BioXP, which increases your allocation in the sale on top of the airdrop.
BioXP Upgrade: We shipped a major BioXP upgrade that opens our launchpad to a much wider audience. Anyone with USDC can now contribute to Ignition Sales, BIO holders can mint BioXP instantly, and BioXP becomes the priority layer when sales fill up, giving you a priority allocation on every new launch.
BIOS: We rolled out Fast Chat Mode (a faster pipeline that runs in an agentic loop and switches to literature search only when needed) and Thinking Traces (real-time reasoning displayed on the main screen during Deep Research) with more features coming up soon. Read more here.
Other Ecosystem Updates include: VitaDAO celebrating CrossBridge Bio's acquisition by Eli Lilly for up to $300M, CerebrumDAO launching Cortex Phase 1 with a $NEURON airdrop and the Cerebrum Stack V1 supplements, and SpineDAO releasing an open dataset of 1,000 synthetic patient records on Science Beach with blockchain-anchored provenance.
PeptAI Ignition: Autonomous Agents for Peptide Drug Discovery
The next BioAgent Ignition Sale is live on Bio. The sale is 12.2X oversubscribed as of this writing, with 610K+ USDC committed by 650+ participants. The sale closes Thursday, May 14 at 1pm UTC. 5% of the total supply is available through the Ignition Sale, with 20% airdropped pro-rata to BIO stakers.
Newsletter
Get the latest updates from the Bio ecosystem
New launches, research progress, and ways to get involved across the Biosphere.
PeptAI is a fleet of autonomous agents for peptide drug discovery. Each agent targets a specific receptor and runs the full 9-gate discovery pipeline 24/7: literature mining, target validation, candidate generation, in silico screening, and ranking. When a candidate clears all nine gates, the agent autonomously commissions and funds its own wet-lab experiment via x402, with every result published openly on Beach Science.
What comes next:
In Q2 2026, PeptAI will deliver its first on-chain wet-lab attestation via @Molecule_sci Labs, marking the first time an autonomous agent commissions, funds, and verifies a real experiment fully onchain.
In Q3 2026, the autonomous iteration cycle will be proven end-to-end, the GLP-1R Gen 1 library will be released, and a design-vs-nature bioRxiv preprint will share results with the broader scientific community.
In Q4 2026, the pipeline scales beyond GPCRs, with new agents targeting receptor classes outside the initial fleet.
In Q1 2027, PeptAI moves into lead optimization at scale and pre-IND scoping, taking validated candidates closer to clinical readiness.
In Q2 2027, the first in vivo studies kick off, with a multi-target portfolio running in parallel across the fleet.
BioXP Upgrade
The next BioXP upgrade is live, opening Ignition Sales to anyone with USDC, letting BIO holders mint BioXP instantly, and using BioXP as the priority layer when sales fill up. The upgrade introduces three new mechanics designed to open Ignition Sales to a wider audience, drive deeper demand for BIO, and reward BioXP holders with priority on every new launch:
Open Launchpad: No BioXP gate to enter. Anyone can now contribute USDC to an Ignition Sale. BioXP becomes the priority layer, not the entry requirement.
Instant BioXP: Mint BioXP right away by spending BIO, no more waiting for it to build up over time. The current price is $0.01 per XP, paid in BIO.
BioXP Drives Allocation: With the door open, BioXP is the lever that decides priority when sales fill up. Pair USDC + BioXP for priority allocation, or contribute USDC only and still get in at the lowest weight.
The goal is simple: open the launchpad to a much bigger audience, drive additional demand for less competitive Ignition Sales, and keep priority for the people who've shown up consistently. Everyone gets in. BioXP decides who gets more. Weekly XP rewards continue for DeSci yappers spreading the word about DeSci, Bio's AI Scientists, and AI agents.
Fast Chat, Thinking Traces & More
We recently shipped several new features for BIOS including:
Fast Chat Mode: A faster pipeline for simple questions that switches to literature search only when needed. It runs in an agentic loop, searching as many times as it needs until it has enough context to give you a complete answer.
Thinking Traces on Screen: BIOS now shows its reasoning on the main loading screen while Deep Research is running, so you can follow along in real time.
In 24 hours, our scientific team and AI scientist infrastructure designed a novel peptide agonist to potentially treat ADHD using @peptai_'s autonomous discovery pipeline on BIOS infrastructure.
Why this matters: no approved orexin agonists exist anywhere. All marketed orexin drugs are dual OX1R/OX2R antagonists for insomnia. Clinical-stage candidates are small molecules for narcolepsy only. OX2R-004 enters genuinely uncharted therapeutic territory.
We did it with PeptAI's novel 9-gate pipeline in one shot, developed by the @BioProtocol community.
This is what DeSci looks like when it works. Hypothesis → computation → candidates → wet lab validation → community-funded.
Network & Community Updates
VitaDAO (@vitadao) - published their March longevity newsletter covering Rubedo's GPX4 modulator hitting positive Phase 1 results in psoriasis and atopic dermatitis, Cyclarity's landmark 7KC review ahead of a Phase 1 readout later this year, the $2.75B Eli Lilly–Insilico deal, ARPA-H committing $144M to aging research, and VitaLabs Season 2 reviewing 100+ applications from six continents. They also celebrated CrossBridge Bio's acquisition by Eli Lilly for up to . @Mykalt45, CrossBridge's CEO, also leads VitaDAO-backed @vitarnabio (ArtanBIO), a gene therapy program going after premature termination codons in aging.
AthenaDAO (@athenabiorg) - attending Vitalist Bay May 14–17, a 4-day longevity festival with 100+ speakers, 50+ workshops, and 40+ activations. The first 15 AthenaBIO members to book get 30% off plus a complimentary DEXA scan with the code ATHENABIO.
CerebrumDAO (@Cerebrum_DAO) - launched Cortex Phase 1, letting users sign and connect their wallets, complete the Brain Health Survey, and save their score, with early participants receiving a $NEURON airdrop. They also introduced the Cerebrum Stack V1, a curated bundle of three supplements selected for specific roles in brain health (Omega-3 EPA+DHA for neuronal membranes, magnesium glycinate for nerve signalling and sleep, creatine monohydrate for ATP production), with all Cognition profits recycled directly into the DAO's research and operations.
DermaDAO (@dermadao) - represented at Paris Blockchain Week, connecting with the broader DeSci and Web3 community to share their work in decentralized dermatology research.
HairDAO (@HairDAO_) - introduced Maxx Precision Dutasteride, a 10x concentration upgrade using the same specialized delivery vehicle with added strength.
SpineDAO (@Spine_DAO) - published their Q1 report focusing on the latest tech developments and community updates, with Spine Reviews going live at @SRS_org 2026 IMAST, the first demonstration of DLT value in spine research. They also released an open dataset on @sciencebeach__ of 1,000 synthetic patient records built from real clinical data in France, validated for accuracy, utility, and privacy with blockchain-anchored provenance.
DeSci Berlin is back for its 5th edition on June 18-19, during @BerBlockWeek bringing together AI researchers, founders, and builders working at the frontier of autonomous agents, AI-driven drug discovery, consciousness research, and decentralized compute. RSVP now.
Bankless covered how Bio is rewriting the DeSci equation, pointing toward a self-sustaining network where AI agents and communities finance and execute science end to end.
Bio founder, Paul Kohlhaas, organized a peptide meetup in Miami, exploring where peptide development is going.
